Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Real-world outcomes of renal denervation in patients with resistant hypertension
Session:
Sessão de Posters 45 - Populações especiais, riscos especiais
Speaker:
Gonçalo Terleira Batista
Congress:
CPC 2026
Topic:
I. Hypertension
Theme:
27. Hypertension
Subtheme:
27.4 Hypertension – Treatment
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Gonçalo Terleira Batista
Abstract
<p>Introduction:<br /> <br /> Resistant hypertension remains a major clinical challenge and an important cardiovascular (CV) risk factor. Renal sympathetic denervation (RDN) has re-emerged as a valuable adjunctive therapy for selected patients who remain hypertensive despite optimal medical management.\ </p> <p>Purpose <br /> <br /> To characterize the baseline clinical profile of patients undergoing RDN and to evaluate changes in ambulatory blood pressure (BP) parameters during follow-up in a real-world setting. </p> <p>Methods <br /> <br /> We conducted a single-center, observational study including 33 patients with resistant hypertension treated with RDN. Clinical, biochemical, and 24-hour ambulatory BP monitoring (ABPM) data were collected at baseline, 6 months, and 12 months. Continuous variables are presented as mean ± SD, and categorical variables as percentages. <br /> Results <br /> <br /> The mean age of the cohort was 62 ± 9 years, and 67% were male. Cardiovascular risk factors were highly prevalent: dyslipidemia (91%) and diabetes mellitus (42%), of which 36% required insulin therapy. Other comorbidities included sleep apnea (58%), coronary artery disease (18%), and prior stroke or transient ischemic attack (15%).<br /> Baseline mean 24-hour systolic BP was 152.5 ± 16.3 mmHg, diastolic BP 87.8 ± 16.5 mmHg, and heart rate 69.5 ± 11.8 bpm. The mean number of ablations per procedure was 27.5 ± 9.5.<br /> At 12 months, mean daytime systolic BP decreased from 157.9 ± 15.6 mmHg to 140.6 ± 17.9 mmHg (Δ = −17.3 ± 10.1 mmHg; p < 0.01), and nighttime systolic BP from 140.6 ± 20.3 mmHg to 125.5 ± 19.2 mmHg (Δ = −15.1 ± 9.8 mmHg; p< 0.01). Diastolic BP showed similar reductions (Δ daytime = −8.1 mmHg; Δ nighttime = −5.5 mmHg).<br /> Overall, 81.5% of patients were classified as responders, defined as a ≥10 mmHg reduction in daytime systolic BP or resolution of symptoms at 12 months. No major periprocedural complications occurred, and renal function and electrolyte levels remained stable during follow-up. </p> <p>Conclusions <br /> <br /> In this real-world cohort of patients with resistant hypertension, RDN resulted in a sustained and clinically significant reduction in ambulatory BP at 12 months, with the majority achieving responder status. These findings support RDN as an effective and safe therapeutic option for patients with long-standing resistant hypertension inadequately controlled with pharmacologic therapy alone.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site